Anika Therapeutics, Inc. (ANIK)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$20.81-0.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · ANIK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 73.7% |
| Our one-year growth estimate | diamond | 4.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 68.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 8 industry peers · Company calendar date is not available
ANIK — credit agreement
Dated 2026-07-14
Entry into a Material Definitive Agreement On July 10, 2026, we entered into a Fifth Amendment to Credit Agreement, or the Fifth Amendment, amending our existing revolving line of credit agreement dated October 24, 2017 with Bank of America, N.A., which revolving line of credit agreement, as amended to date (including by such Fifth Amendment), we refer to as the Amended Agreement. Under the Amended Agreement, Bank of America, N.A. serves as administrative agent, issuer of letters of credit an…
Why it matters: This margin shows Anika is doing better with operations. They are managing costs well.
Supportive ifAdjusted EBITDA margin reaches or exceeds 5% in Q2.
Worry ifAdjusted EBITDA margin falls below 5% in Q2.
Why it matters: FDA feedback will determine the timeline and success of the Hyalofast product launch.
Watch forPositive feedback from the FDA on Hyalofast PMA clinical endpoints.
Also watch forNegative feedback or further delays from the FDA on Hyalofast PMA.
Why it matters: This shows Anika can keep its revenue goals even with market problems.
Supportive ifQ2 total revenue growth meets or exceeds 1% year over year.
Worry ifQ2 total revenue growth falls below 1% year over year.
Why it matters: Completion would be a key step toward filing the NDA and future sales growth.
Supportive ifThe bioequivalence study for Cingal is complete.
Worry ifThere are delays in starting or finishing the bioequivalence study.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$154 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $342 loss on $10,000 · 3.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,256 loss on $10,000 · 22.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Progress on this submission is key for future revenue and market positioning.
Watch forAnnouncement of the Cingal NDA submission within the next quarter.
Also watch forDelay in the Cingal NDA submission timeline or lack of updates.
Why it matters: If healthcare sector growth speeds up, it could help Anika's performance. Anika's results are tied to sector trends.
Supportive ifHealthcare sector revenue growth returns to near 10% or higher.
Worry ifHealthcare sector revenue growth is under 10%. This shows it is still slowing down.
Why it matters: Keeping this revenue matters for the company's performance. It is also important for investors.
Watch forOEM Channel revenue remains between $61 million and $64.5 million.
Also watch forOEM Channel revenue falls below $61 million.
Why it matters: If the margin drops, it shows problems with cost management and efficiency.
Worry ifAdjusted EBITDA margin falls below 13% for Q3.
Less concerning ifAdjusted EBITDA margin stays at or above 13%.
Why it matters: Changes in leaders can affect how a company runs. Stability helps keep investor trust.
Watch forNo new leader changes reported. This shows the company is stable.
Also watch forMore leaders are leaving or changing. This may mean the company is unstable.
Why it matters: A slowdown in Commercial Channel growth may mean less demand or more competition.
Worry ifQ3 Commercial Channel revenue growth below 12% year over year.
Less concerning ifCommercial Channel revenue growth remains at or above 12% year over year.
Why it matters: Moving forward with the Cingal NDA submission is important for future revenue and market share.
Supportive ifCompletion of the bioequivalence study for Cingal and start of NDA submission.
Worry ifDelays in the bioequivalence study or NDA submission.